Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial

Author(s):
Aslanyan, M.G.; Kroeze, L.I.; Langemeijer, S.M.C.; Koorenhof-Scheele, T.N.; Massop, M.; Hoogen, P. van; Stevens-Linders, E.; Locht, L.T. van de; Tonnissen, E.; Heijden, A. van der; Silva-Coelho, P. da; Cilloni, D.; Saglio, G.; Marie, J.P.; Tang, R.P.; Labar, B.; Amadori, S.; Muus, P.; Willemze, R.; Marijt, E.W.A.; Witte, T. de; Reijden, B.A. van der; Suciu, S.; Jansen, J.H.
Published
2014
Publication type
Article / Letter to editor
TET2 mutationsAcute myeloid leukemiaTET2 expressionPrognosis
Date issued
2014-08-31
Language
English
Is part of
Annals of Hematology (2014), Vol. 93, no. 8, p. 1401-1412
hdl
1887/104435
doi
10.1007/s00277-014-2055-7